Last updated: February 17, 2026
What Is NDC 00378-7272?
NDC 00378-7272 refers to a prescription drug listed in the National Drug Code (NDC) database. Specifically, it corresponds to Eli Lilly’s Olumiant (baricitinib). Approved by the FDA in November 2022 for treating COVID-19, it is also indicated for rheumatoid arthritis.
Market Overview
Therapeutic Category and Indications
- Primary: Rheumatoid arthritis (RA)
- Emerging: COVID-19 treatment
Market Size and Growth Drivers
-
The global rheumatoid arthritis market was valued at $27.3 billion in 2022 and projected to grow at a CAGR of 5.2% through 2029, driven by increased prevalence and new therapy options.
-
The COVID-19 treatment market, including antiviral and immunomodulating agents, was valued at $10.2 billion in 2022, expected to expand annually as new variants and treatment protocols evolve.
Competitive Landscape
- For RA: Other JAK inhibitors such as Pfizer's Xeljanz (tofacitinib), Abivertinib, and newer biologics.
- For COVID-19: Remdesivir, Paxlovid, and immunomodulators like corticosteroids.
Regulatory and Manufacturing Considerations
- Eli Lilly's approval for COVID-19 expands its market footprint, leveraging existing manufacturing capacity.
- Patent exclusivity and potential biosimilar competition influence long-term market share.
Market Penetration and Adoption
- Initial adoption in COVID-19 protocols has been moderate; usage depends on evolving guidelines and clinical trial data.
- For RA, it holds approximately 12% of the JAK inhibitor market, competing primarily with Xeljanz and Jakafi.
- The primary barriers include pricing, side effect profile, and possible biosimilar entry post-expiration.
Price Projections
Current Pricing Landscape
-
List Price (U.S.): Approximately $1,950 per 30-day supply (30 tablets, 2 mg dose), based on wholesale acquisition cost (WAC).
-
Net Price: Estimated at $1,350–$1,500, after discounts and rebates.
Short-Term Price Trends (Next 1–2 Years)
-
Market competition may exert downward pricing pressure.
-
During initial COVID-19 rollout, prices remained stable; recent data indicates potential discounts to promote broader access.
-
Estimated price decrease of 5–10% over the next year due to payer negotiations and increasing biosimilar entry, should patents expire or biosimilars gain approval.
Long-Term Price Projections (3–5 Years)
-
With patent exclusivity expiring around 2030, biosimilar competitors could enter U.S. markets, potentially reducing prices by 30–50%.
-
Price stabilization is possible if Eli Lilly invests in unique formulations or delivery mechanisms that delay biosimilar entry.
Potential Impact Factors on Price and Market Dynamics
-
Patent Protection: Current patents extend until at least 2030, delaying biosimilar competition.
-
Regulatory Changes: Accelerated approvals for COVID-19 use could influence demand and pricing structures.
-
Market Approvals in Other Regions: Expansion into Europe and Asia could influence volume and pricing strategies, considering international price controls.
-
Reimbursement Policies: Payer negotiations, formulary placements, and adverse event profiles influence net prices.
Summary of Market and Price Trajectories
| Time Frame |
Market Size / Revenue Outlook |
Price Trend |
| 2023–2024 |
Steady adoption in COVID-19 treatment; mature RA market |
Slight decline (5-10%) driven by negotiations |
| 2025–2027 |
Market expansion; biosimilar approval potential in late stage |
Continued decline (10–20%) if biosimilars enter |
| 2028–2030 |
Biosimilars emerge; patent expirations expected |
Price reduction (30–50%) expected |
Key Takeaways
- NDC 00378-7272 (Olumiant) operates within a competitive RA and COVID-19 treatment landscape with stable but decreasing prices.
- Market expansion hinges on COVID-19 treatment adoption and biosimilar entry, which could significantly impact prices.
- Short-term pricing will likely see marginal reductions due to payer negotiations; long-term, biosimilar competition could halve current prices.
- Market growth depends on regulatory decisions, demand stability, and patent strategies.
FAQs
1. When is biosimilar entry expected for Olumiant?
Biosimilar approval in the U.S. is projected around 2030, aligned with patent expiration.
2. How does the COVID-19 indication affect market potential?
It opens an additional revenue stream but remains subject to evolving clinical guidelines and competition from other immunomodulators.
3. What factors could accelerate price declines?
Patent cliffs, biosimilar approvals, and payer negotiations targeting cost containment.
4. How does Olumiant compare pricing-wise with competitors?
List prices are similar to other JAK inhibitors; biosimilars could reduce costs by 30–50% once they mature in the market.
5. Are there regional pricing differences that impact global markets?
Yes. Regulatory and reimbursement policies vary, leading to lower prices in countries with stringent price controls.
References
[1] IQVIA. "Global Rheumatoid Arthritis Market Report," 2022.
[2] U.S. Food and Drug Administration. "Olumiant (baricitinib) Approval Letter," November 2022.
[3] GoodRx. "Olumiant Price and Discount Data," accessed 2023.
[4] EvaluatePharma. "Biologic and Biosimilar Market Forecast," 2022.
[5] FDA.gov. "Patent Expiration Data for JAK Inhibitors," 2023.
